.png "Gregory Sullivan, MD photo")
Tonix Pharmaceuticals Inc
Chatham, NJ, United States
Gregory M. Sullivan, MD is Chief Medical Officer at Tonix Pharmaceuticals, leading clinical development across a CNS portfolio that includes fibromyalgia, PTSD, major depressive disorder, migraine, long COVID, and cocaine intoxication. Since joining Tonix in 2014, he has guided multiple programs from pre-IND through NDA, including the NDA for TNX-102 SL in fibromyalgia, approved by the FDA in August 2025. Dr. Sullivan serves as Tonix’s primary medical liaison with the FDA, EMA, and PMDA and has built cross-functional teams to deliver successful Phase I–III trials.
Previously, Dr. Sullivan was Assistant Professor of Clinical Psychiatry at Columbia University and a Research Scientist at the New York State Psychiatric Institute, where he led NIH- and foundation-funded studies on affective and anxiety disorders and received a K08 Mentored Clinical Scientist Award.
He has authored over 50 peer-reviewed publications on topics including stress neurobiology, suicidality, and serotonin receptor function in mood and anxiety disorders. Dr. Sullivan earned his MD from Columbia University, a BA in Biology from UC Berkeley, and completed NIH-funded fellowships in molecular immunology and affective disorders. He is a member of the Society for Neuroscience, the Society of Biological Psychiatry, and the American Society of Clinical Psychopharmacology.
ORCID: 0000-0002-1707-4490
Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
